Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells---Cdc2 activity is up-regulated by targeting WEE1

Clinics

Volumn 68, Issue 6, 2013, Pages 825-833

  Chen, Binghai ^a,b   Duan, Lujing ^b   Yin, Guangming ^a   Tan, Jing ^a   Jiang, Xianzhen ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

MiR 381; MiR 424; MiRNA; Synergistic effect; WEE1

Indexed keywords

CDC2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN B; MICRORNA; MIRN424 MICRORNA, HUMAN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; WEE1 PROTEIN, HUMAN;

ARTICLE; CELL TRANSFORMATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PHYSIOLOGICAL PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN B; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; UP-REGULATION;

EID: 84879313822     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(06)17     Document Type: Article

References (34)

1. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets. 2012, 16(8):747-59, http://dx.doi.org/10.1517/14728222.2012.696102.
2. Hilgers V, Bushati N, Cohen SM. Drosophila microRNAs 263a/b confer robustness during development by protecting nascent sense organs from apoptosis. PLoS Biol. 2010;8:e1000396, http://dx.doi.org/10.1371/journal.pbio.1000396.
3. Liang LH, He XH. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin. 2011;32(11):1311-20, http://dx.doi.org/10.1038/aps.2011.103.
4. Ciaudo C, Servant N, Cognat V, Sarazin A, Kieffer E, Viville S, et al. Highly dynamic and sex-specific expression of microRNAs during early ES cell differentiation. PLoS Genet. 2009;5(8):e1000620, http://dx.doi.org/10.1371/journal.pgen.1000620.
5. Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, et al. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica. 2012;97(4)586-94, http://dx.doi.org/10.3324/haematol.2011.048132.
6. Zhang A, Liu Y, Shen Y, Xu Y, Li X. miR-21 modulates cell apoptosis by targeting multiple genes in renal cell carcinoma. Urology. 2011;78(2):474. e13-9, http://dx.doi.org/10.1016/j.urology.2011.03.030.
7. Lindqvist A, Rodriguez-Bravo V, Medema RH. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol. 2009;185(2):193-202, http://dx.doi.org/10.1083/jcb.200812045.
8. Yamashita K. Cdc2 activation by phosphorylation. Seikagaku. 1996;68(5):367-71.
9. Fasulo B, Koyama C, Yu KR, Homola EM, Hsieh TS, Campbell SD, et al. Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry. Mol Biol Cell. 2012;23(6):1047-57, http://dx.doi.org/10.1091/mbc.e11,-1,xxx/mbc.e11-10-0832.
10. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40(2):477-86, http://dx.doi.org/10.1093/nar/gkr697.
11. Mir SE, De Witt HP, Krawczyk PM, Balaj L, Claes A, Niers JM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010;18(3):244-57, http://dx.doi.org/10.1016/j.ccr.2010.08.011.
12. Li J, Wang Y, Sun Y, Lawrence TS. Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Radiat Res 2002;157:322-330, http://dx.doi.org/10.1667/0033-7587(2002)157[0322:WTTIGP]2.0.CO;2.
13. Garimella SV, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2012;10(1):75-85, http://dx.doi.org/10.1158/1541-7786.MCR-11-0500.
14. Blenk S, Engelmann JC, Pinkert S, Weniger M, Schultz J, Rosenwald A, et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer. 2008;8:106, http://dx.doi.org/10.1186/1471-2407-8-106.
15. Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle. 2002;1(6):362-8, http://dx.doi.org/10.4161/cc.1.6.257.
16. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. Starbase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIPSeq and Degradome-Seq data. Nucleic Acids Res. 2011;39(Database issue):D202-9, http://dx.doi.org/10.1093/nar/gkq1056.
17. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 2013;32(8):976-87, http://dx.doi.org/10.1038/onc.2012.121.
18. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez- Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cellautonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol. 2011;31(11):2595-606, http://dx.doi.org/10.1161/ATVBAHA.111.236521.
19. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol. 2012;5:26, http://dx.doi.org/10.1186/1756-8722-5-26.
20. Wang S, Wang L, Bayaxi N, Li J, Verhaegh W, Janevski A, et al. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut. 2013;62(2):280-9, http://dx.doi.org/10.1136/gutjnl-2011-301554.
21. Li X, Shen S, Wu M, Li X, Xiong W, Lu J, et al. Transcriptomic regulation and molecular mechanism of polygenic tumor at different stages. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(7):585-91.
22. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR- 200c. J Pathol. 2008;216(4):418-27, http://dx.doi.org/10.1002/path.2437.
23. Kim YJ, Ketter R, Steudel WI, Feiden W. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128(1):118-25.
24. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30(1):83-9.
25. Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O. Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene. 2005;24(12):1973-81, http://dx.doi.org/10.1038/sj.onc.1208408.
26. Nishimura T, Shimaoka T, Kano K, Naito K. Insufficient amount of Cdc2 and continuous activation of Wee1 B are the cause of meiotic failure in porcine growing oocytes. J Reprod Dev. 2009;55(5):553-7, http://dx.doi.org/10.1262/jrd.09-072A.
27. Indovina P, Giordano A. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther. 2010;9(7):523-5.
28. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res. 2012;14(3):R77, http://dx.doi.org/10.1186/bcr3187.
29. De Witt HP, Mir SE, Noske D, Van Noorden CJ, Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res. 2011. 1;17(13):4200-7.
30. Carrassa L, Chila R, Lupi M, Ricci F, Celenza C, Mazzoletti M, et al. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle. 2012;11(13):2507-17, http://dx.doi.org/10.4161/cc.20899.
31. Qi J, Yu JY, Shcherbata HR, Mathieu J, Wang AJ, Seal S, et al. microRNAs regulate human embryonic stem cell division. Cell Cycle. 2009;8(22):3729-41, http://dx.doi.org/10.4161/cc.8.22.10033.
32. Peter ME. Targeting of mRNAs by multiple miRNAs: The next step. Oncogene. 2010;29(15):2161-4, http://dx.doi.org/10.1038/onc.2010.59.
33. Bandi N, Vassella E. Mir-34a and miR-15a/16 are co-regulated in nonsmall cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55, http://dx.doi.org/10.1186/1476-4598-10-55.
34. Nachmani D, Lankry D, Wolf DG, Mandelboim O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol. 2010;11(9):806-13, http://dx.doi.org/10.1038/ni.1916.